1. Welcome (5 min)
                                                              
2. Best Practices from the Field: 15 min each  (75 min)
   1. 4Ms Working Flowcharts & Documentation                                    
                                         
   2. Assessing What Matters                                                                   
                   
   3. Age Friendly Health Systems: Bringing SON and NH Collaboration to Life                        
                                         
   4. The Who and How of Supporting What Matters Most                  
                 
   5. VA Pittsburgh Healthcare System and AFHS                                   
                             

1. Bringing it all together and next steps      (10 min)                                             
                                               
2. Updates from the state  (25 min)
    DHS|OLTL Updates                                                           

• NF quality incentive update
• End of Public health emergency for NFs from DHS perspective
• Future direction
   
    DOH

• Introduction of Long-Term Care Transformation Office charter mission / vision
• Update on Quality Investment Pilot
• Future direction
• End of COVID Emergency
   

1. PADONA Conference (3 min)        
                       

          Wrap up and Closing           (2 min)

Disclaimer Statement

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine.  Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses